• United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing
emphycorp logo
emphycorp logo
  • About Us
    • About Us
    • Management and Advisors
    • OUR MEDICAL STUDIES
  • Our Drug Pipeline
    • Our Drug Pipeline
    • PULMONARY FIBROSIS TREATMENT®
    • COVID-19 TREATMENT®
    • COVID-19 LONG HAULERS TREATMENT®
    • FLU TREATMENT®
    • UNMET NEEDS BREATHING TREATMENT®
    • NON-STEROIDAL COPD NASAL SPRAY®
    • 70% LOWER STEROID COPD®
    • NON-STEROIDAL ALZHEIMER’S NASAL SPRAY®
    • CONCUSSIONS TREATMENT®
    • DRUG FREE CANCER PRE-TREATMENT®
    • SMOKING CESSATION ORAL SPRAY®
  • Conditions We Can Treat
    • HYPOXEMIA
    • PULMONARY FIBROSIS
    • COVID-19
    • COVID LONG HAULERS
    • FLU
    • ASTHMA
    • COPD
    • EMPHYSEMA
    • SARCOIDOSIS
    • CYSTIC FIBROSIS (CF)
    • CHRONIC BRONCHITIS
    • INTERSTITIAL LUNG DISEASE
    • VIRAL and BACTERIAL Infections
  • FDA Submissions
    • REGULATION OF NITRIC OXIDE
    • SODIUM PYRUVATE
    • N115 FDA SUBMISSIONS
  • Contact Us
    • Investor Relations
    • Partnerships
  • News/Press/Blog
    • Emphycorp News & Peer Reviewed Articles
    • PRESS RELEASES
    • Blog
    • NEW PULMONARY FIBROSIS TREATMENT
  • United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing

Blog

Blog
  1. Home
  2. Archive by Category "Blog"

Blog

  • Show all
  • Uncategorized
  • Medical News

February 10, 2022

First Biotech to complete a Phase III for Long Hauler COVID-19 symptoms


by Emphycorp

long covid treatment

November 7, 2021

 Study evaluates treatment of ‘long COVID’ patients


by Emphycorp

lungs with bio marker

November 7, 2021

N115 Nasal Spray Found to Improve Lung Function in PF Patients


by Emphycorp

November 7, 2021

European Journal of Respiratory Medicine Peer Reviewed Publication – “Inhalation of Sodium Pyruvate to Reduce the Symptoms and Severity of Respiratory Diseases Including COVID-19, Long COVID, and Pulmonary Fibrosis


by Emphycorp

October 18, 2021

The Market of Emphycorp


by Emphycorp

Emphycorp proprietary N115

October 18, 2021

Emphycorp Proprietary N115


by Emphycorp

October 18, 2021

New Non-Steroidal Treatment for Pulmonary Fibrosis


by Emphycorp

October 17, 2021

EMPHYCORP INFLUENZA AND COVID-19 ANIMAL AND HUMAN STUDIES


by Emphycorp


by Emphycorp

emphycorp logo white

Terms and Conditions

Focus Pages

  • About Emphycorp
 
  • Emphycorp News
 
  • Investor Relations

Address

84 Park Avenue, Suite E-102
Flemington, New Jersey
08822 USA

Start a conversation

SALES: (973) 586-4421
MARKETING: (973) 586-4421

© 2025 Emphycorp Inc. . All rights reserved

© 2025 Emphycorp Inc. . All rights reserved

Privacy Preference Center

Privacy Preferences